Neoleukin Therapeutics Stock Price

-0.24 (-1.97%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Neoleukin Therapeutics Inc NLTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.24 -1.97% 11.96 00:00:06
Open Price Low Price High Price Close Price Prev Close
12.31 11.77 12.345 11.96 12.20
Bid Price Ask Price Spread News
11.20 15.00 3.80 1 -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,782 121,326 $ 12.03 $ 1,459,983 392,495 9.63 - 18.13
Last Trade Time Type Quantity Stock Price Currency
17:03:06 formt 985 $ 11.96 USD

Neoleukin Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 501.54M 41.93M 35.82M $ - $ - -2.41 -27.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Neoleukin Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NLTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week12.0112.7011.6812.14149,174-0.05-0.42%
1 Month11.3313.3011.0512.01249,6900.635.56%
3 Months12.9014.9010.8112.44214,647-0.94-7.29%
6 Months12.1817.9510.0713.00307,154-0.22-1.81%
1 Year12.5318.139.6313.18319,573-0.57-4.55%
3 Years3.9818.132.5311.40328,2707.98200.5%
5 Years3.9818.132.5311.40328,2707.98200.5%

Neoleukin Therapeutics Description

Neoleukin Therapeutics Inc operates as a biopharmaceutical company. It generates immunotherapies using de novo protein design technology. The firm uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises of NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.

Your Recent History
Neoleukin ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.